Takeda Oncology
Justin Miano is a seasoned finance professional with extensive experience in the pharmaceutical and biotechnology industries. Currently serving as Senior Director and Head of Finance for Oncology FP&A and Global Functions at Takeda Oncology since March 2021, Justin oversees financial planning and analysis for various global functions and manages budget consolidation across regions and countries. Prior to this role, Justin held senior financial leadership positions at Takeda and Shire, focusing on global real estate, facilities, procurement, and corporate functions. Justin's career includes previous roles in finance at PAREXEL and Novartis Vaccines, as well as foundational experiences in GE's corporate finance programs. Justin holds a Bachelor of Science in Finance from Providence College.
This person is not in any teams
This person is not in any offices
Takeda Oncology
20 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.